We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Technopath Clinical Diagnostics


Leica Biosystems develops and supplies cancer diagnostics devices and solutions in the areas of histology, digital pa... read more Featured Products: More products

Download Mobile App


ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.

Novel Serum Biomarker Investigated for Early Gastric Cancer Diagnosis

By LabMedica International staff writers
Posted on 03 Nov 2021
Print article
Image: The BOND-MAX Fully Automated IHC and ISH Staining System (Photo courtesy of Leica  Microsystems)
Image: The BOND-MAX Fully Automated IHC and ISH Staining System (Photo courtesy of Leica Microsystems)
Gastric cancer (GC) is one of the most common causes of cancer-related death worldwide. More importantly, most reported GC cases are in developing countries. The high mortality of GC is often due to its nonspecific symptoms and delayed diagnosis.

Early detection is key step in the management of patients and survival improvement. Gastric endoscopy is widely used for GC screening. Magnifying endoscopy (ME) with narrow band imaging (ME-NBI) is also an effective tool for real-time endoscopic diagnosis of early gastric cancer (EGC). However, using these tools, identifying subtle lesions or differentiation between inflammation and early intraepithelial neoplasia is still challenging.

Gastroenterologists at the Shanghai General Hospital (Shanghai, China) enrolled a total of 108 patients who presented with GC between July 2016 and June 2018. The subjects included 38 cases of EGC and 70 cases of advanced gastric cancer (AGC). Also included were 28 patients with low-grade intraepithelial neoplasia (LGN, precancerous group), 37 patients with chronic superficial gastritis (CSG) associated with Helicobacter pylori infection (Hpi), 49 patients with other system malignant tumors (OST) and 178 healthy volunteers (healthy control, HC).

Serum samples from 20 patients with EGC and 20 HCs were selected for polypeptide analysis via mass spectrometry. A nanoliter flow HPLC system, EASY-nLC 1000, with a trap column and a C18 column was used in this study and the analysis was performed using the Orbitrap Elite system (Thermo Scientific, Waltham, MA, USA). To confirm the mass spectrometry results, serum samples from 16 patients with EGC, 16 patients with AGC, and 16 HCs were subjected to immunoblotting against inter-alpha-trypsin inhibitor heavy chain 4 (ITIH4).

The tumor tissues of 20 patients with GC and their adjacent normal tissues were embedded, sectioned, and placed in Leica Bond-Max automatic immunohistochemical machine (Leica Microsystems, Berlin, Germany). The expression profiles of ITIH4 in 312 serum samples, including 26 EGC, 48 AGC, 26 LGN, 37 Hpi, 49 OST, and 126 HC serum samples, were determined using enzyme-linked immunosorbent assay (ELISA, R&D Systems, Minneapolis, MN, USA). To determine the expression levels of target molecules in blood, exosomes in serum samples were isolated, identified, and analyzed.

The investigators reported that ITIH4 was identified as a key biomarker in patients with EGC. Its expression level in serum from the EGC group, which showed the highest specificity (94.5%), was significantly higher than those in sera from other GC groups as well as the control. Western blot analysis, immunohistochemical staining, and exosome analysis also confirmed ITIH4 expression in sera from patients with GC, but not in those from healthy individual.

The authors concluded that the serum ITIH4 expression level is a promising biomarker for the early diagnosis of GC. ITIH4 levels in serum samples from patients at the early stage of GC were significantly higher than those in serum samples from patients with GC at the advanced stage or HCs. This finding indicated that serum ITIH4 levels can be a potential biomarker for early stage GC diagnosis. The study was published on October 20, 2021 on the journal Clinica Chimica Acta.

Related Links:
Shanghai General Hospital
Thermo Scientific
Leica Microsystems
R&D Systems

Gold Supplier
SARS-COV-2 PLUS UK Real Time PCR kit
Silver Supplier
COVID-19 Ag Self Test
OnSite COVID-19 Ag Self Test
Vented Safety Enclosures
VSE Balance Enclosures
Clinical Chemistry Reagents
SEKURE Clinical Chemistry Reagents

Print article


Molecular Diagnostics

view channel
Image: Absence of nuclear immunohistochemical staining of MSH2 protein (A) and presence of MLH1 protein (B) in urothelial cell carcinoma of the urinary bladder of a patient carrying a germline MSH2 mutation. Observe the nuclear staining in stromal cells as an internal control (Photo courtesy of Radboud University Nijmegen Medical Centre)

Simple Urine Test Detects Urothelial Cancers in Lynch Syndrome Patients

Lynch Syndrome (LS) is an inherited genetic disorder that carries a high risk of cancer. LS is caused by mutations affecting MLH1, MSH2, MSH6 or PMS2 genes. More than one in 300 people have LS but most... Read more


view channel
Image: The Gazelle Hb Variant Test for screening, diagnosis and management of sickle cell disease and related hemoglobinopathies at the point of care (Photo courtesy of Hemex Health)

Point-of-Care Device Accurately Rapidly Diagnoses Sickle Cell Disease

Hemoglobinopathies are the most common autosomal hereditary disorders. Approximately 7% of the global population carries hemoglobin gene mutation including structural hemoglobin variants like sickle hemoglobin... Read more


view channel
Image: The IMMULITE 2000 XPi Immunoassay System provides multiple tests on a single, easy-to-use analyzer, including the thyroid-stimulating immunoglobulin assay (Photo courtesy of Siemens Healthcare)

Immunoassays Evaluated for Thyroid-Stimulating Receptor Antibody in Graves’ Disease

Graves' disease (GD), also known as toxic diffuse goiter, is an autoimmune disease that affects the thyroid. It frequently results in and is the most common cause of hyperthyroidism and it also often results... Read more


view channel
Image: The sciREADER CL2 enables high quality digital colorimetric imaging of various support formats (Photo courtesy of SCIENION)

Multiplex Immunoassay Developed for Confirmation and Typing of HTLV Infections

Human T-Cell Lymphotropic Viruses (HTLV) type 1 and type 2 account for an estimated five to 10 million infections worldwide and are transmitted through breast feeding, sexual contacts and contaminated... Read more


view channel

AI Accurately Detects and Diagnoses Colorectal Cancer from Tissue Scans As Well or Better Than Pathologists

Artificial intelligence (A) can accurately detect and diagnose colorectal cancer from tissue scans as well or better than pathologists, according to a new study. The study, which was conducted by researchers... Read more


view channel
Image: PKeye Workflow Monitor System (Photo courtesy of PerkinElmer, Inc.)

PerkinElmer’s New Cloud-Based Platform Enables Laboratory Personnel to Remotely Manage Its Instruments in Real-Time

PerkinElmer, Inc. (Waltham, MA; USA) has launched its PKeye Workflow Monitor, a cloud-based platform enabling laboratory personnel to remotely manage and monitor their PerkinElmer instruments and workflows... Read more


view channel

Global Point of Care Diagnostics Market to Top USD 35 Billion by 2027 Due to Rising Diabetic Cases

The global point of care diagnostics market is projected to grow at a CAGR of close to 6% from more than USD 23 billion in 2020 to over USD 35 billion by 2027, driven by an increase in the number of diabetic... Read more
Copyright © 2000-2021 Globetech Media. All rights reserved.